Tibolone and its effects on bone: a review

  title={Tibolone and its effects on bone: a review},
  author={B. Berning and H J Coelingh Bennink and Bcjm Fauser},
  pages={120 - 136}
This review examines the evidence for the effects of tibolone on bone. Tibolone is a synthetic steroid with a mixed (estrogenic–progestogenic–androgenic) hormonal profile. Data suggest a complex receptor-mediated as well as metabolic regulation of the activity of tibolone at target tissue level. It has been shown that tibolone can prevent axial and appendicular bone loss induced by ovariectomy and/or a low calcium diet in young and mature rats. In addition, tibolone increases trabecular and… Expand
Androgen effects on bone and muscle.
Endogenous androgens increase bone mineral density in both adolescent and adult premenopausal women and have an additive effect on BMD when combined with E therapy and have the further advantage of being protective to the endometrium in E-treated women. Expand
Application of a mechanism-based disease systems model for osteoporosis to clinical data
The fitted model enabled characterization of the critical time scales involved in disease progression, the dynamics of the system during onset and offset of the therapeutic intervention, and the distinction between responders and low-responders to tibolone treatment. Expand
Therapie der Osteoporose
Observation studies and meta-analyses have shown that vertebral and non-vertebral fractures are less common during hormone replacement therapy and alendronate, risedronate and calcium-vitamin D lower the risk of hip fractures. Expand
A Review of Analytical Methods for the Determination of Tibolone: Pharmacokinetics and Pharmaceutical Formulations Analysis and Application in Doping Control
Tibolone is a synthetic steroid commercialized by Organon under the brand name Livial (Org OD14), which is used in hormone therapy for menopause management and treatment of postmenopausalExpand
Spanish Menopause Society position statement: use of tibolone in postmenopausal women
In Spain, tibolone is the most prescribed hormonal treatment, and one of the most common complaints among postmenopausal women is change in sexual drive, so a panel of experts from the Spanish Menopause Society met to develop usage recommendations based on the best evidence available. Expand
Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene
It is confirmed that postmenopausal hypoestrogenism leads to increased fat content and serum leptin levels and raloxifene and tibolone seem to prevent post menopausal body composition changes without significant modifications of serum leptin Levels. Expand
Is hormone therapy still an option for the management of osteoporosis?
The main results from the estrogen and progestogen arm of the Women’s Health Initiative (WHI)1 reverberated around the world because they were taken out of context and the hazards of hormone therapyExpand
Where are we with postmenopausal hormone therapy in 2005?
  • P. Lam, T. Chung, C. Haines
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2005
What the authors know and do not know about postmenopausal hormone therapy, including the evidence on novel choices such as raloxifene and tibolone are discussed, are discussed. Expand


Tibolone, a Steroid with a Tissue‐Specific Hormonal Profile, Completely Prevents Ovariectomy‐Induced Bone Loss in Sexually Mature Rats
  • A. Ederveen, H. Kloosterboer
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1999
Treatment with tibolone for 4 weeks prevented OVX‐induced bone loss by suppressing both bone resorption and bone turnover in a similar way as EE2, however, the frequency of dosing is more important for EE2 than for tIBolone. Expand
Tibolone: prevention of bone loss in late postmenopausal women.
Within 2 yr of treatment, tibolone increases bone mass in the spine and prevents bone loss in the forearm in late postmenopausal women determined by densitometry and several biochemical parameters of bone turnover. Expand
Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women.
Since tibolone effected a greater increase in spine BMD than did either conjugated equine estrogen with progestogen or transdermal estradiol alone, it is particularly suitable for older women who often have more advanced osteoporosis and who would not accept a return of cyclical bleeding. Expand
Effects of 16 weeks of treatment with tibolone on bone mass and bone mechanical and histomorphometric indices in mature ovariectomized rats with established osteopenia on a low-calcium diet.
Tibolone suppresses the accelerated bone turnover induced by a combination of ovariectomy and low dietary calcium, and indicates that tibolones may be a potentially useful drug for the treatment of postmenopausal osteoporosis. Expand
Effects of tibolone (Org OD14) treatment for 3 months on ovariectomy-induced osteopenia in 8-month-old rats on a low-calcium diet: preventive testing for 3 months.
It is indicated that tibolone prevents reduction in bone mass associated with osteopenia by reducing increased trabecular bone resorption induced by a combination of ovx and a low-Ca diet. Expand
Treatment of postmenopausal osteoporosis with transdermal estrogen.
Transdermal estradiol treatment is effective in postmenopausal women with established osteoporosis and vertebral fractures and Histomorphometric evaluation of iliac biopsy samples confirmed the effect of estrogen on bone formation rate per bone volume. Expand
The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss.
It is concluded that percutaneous estradiol is effective as preventive therapy of postmenopausal bone loss and that addition of progesterone does not influence bone or calcium metabolism. Expand
Tibolone and its metabolites: Pharmacology, tissue specificity and effects in animal models of tumors
Tibolone is a steroid with weak estrogenic, progestogenic and androgenic properties that can be used as an alternative to conventional hormone replacement therapy in postmenopausal women. Tibolone isExpand
Prevention of Postmenopausal Bone Loss Using Tibolone or Conventional Peroral or Transdermal Hormone Replacement Therapy with 17β‐Estradiol and Dydrogesterone
Tibolone can be regarded as an alternative to conventional HRT to prevent postmenopausalBone preservation was observed in all three treatment groups as compared with controls, without significant differences among treatment regimens. Expand
Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study.
Tibolone prevents early postmenopausal bone loss by inducing an increase in trabecular and phalangeal BD as compared to pretreatment values after 2 years of tibolones. Expand